Sugi Predict

Sugi Predict / Compounds / SCHEMBL1095494

SCHEMBL1095494

SCHEMBL1095494

C[C@@H]1CN(C)CCc2ccc(Cl)cc21

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD3 P35462 15/20 0.54
▸ HTR1A P08908 10/20 0.54
▸ HTR2A P28223 5/20 0.54
▸ HRH1 P35367 4/20 0.54
▸ HTR2C P28335 3/20 0.54
▸ HTR2B P41595 3/20 0.54
▸ KCNH2 Q12809 2/20 0.54
▸ ADRB1 P08588 1/20 0.54
▸ ADRA2A P08913 1/20 0.54
▸ ADRA2B P18089 1/20 0.54
▸ ADRA2C P18825 1/20 0.54
▸ CNR1 P21554 1/20 0.54
▸ SLC6A2 P23975 1/20 0.54
▸ SLC6A4 P31645 1/20 0.54
▸ DRD2 P14416 15/20 0.50
▸ DRD1 P21728 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1105045 1.00 DRD3 (0.54) DRD3HTR1AHTR2AHRH1HTR2C
SCHEMBL1095493 1.00 DRD3 (0.54) DRD3HTR1AHTR2AHRH1HTR2C
SCHEMBL2695341 0.84 HTR1A (0.54) DRD3HTR1AHTR2AHRH1HTR2C
SCHEMBL16885002 0.84 HTR1A (0.54) DRD3HTR1AHTR2AHRH1HTR2C
SCHEMBL16364431 0.84 HTR1A (0.54) DRD3HTR1AHTR2AHRH1HTR2C
SCHEMBL15099564 0.82 DRD1 (0.47) DRD3HTR1AHTR2ASLC6A2SLC6A4
SCHEMBL2202254 0.81 DRD1 (0.46) DRD3HTR1AHTR2ADRD2DRD1
SCHEMBL2202871 0.81 HTR2A (0.54) HTR2AHRH1HTR2CHTR2BADRA2A
SCHEMBL2276907 0.81 DRD1 (0.68) DRD3HTR1AHTR2ADRD2DRD1
SCHEMBL3770992 0.81 DRD1 (0.68) DRD3HTR1AHTR2ADRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374796-B1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes ARENA PHARM INC (US) 2018-02-28 — — EP disclosed
US-20160250223-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2016-09-01 — — US disclosed
US-20160024014-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2016-01-28 — — US disclosed
US-8993750-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2015-03-31 — — US disclosed
US-20150087634-A1 5HT2C RECEPTOR MODULATOR COMPOSITIONS ARENA PHARMACEUTICALS, INC. 2015-03-26 — — US disclosed
US-20150045552-A1 5HT2C RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2015-02-12 — — US disclosed
US-8846906-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-8575149-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2013-11-05 — — US disclosed
US-8546379-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2013-10-01 — — US disclosed
US-8546378-B2 5HT2C receptor modulator compositions and methods of use ARENA PHARMACEUTICALS, INC. (US) 2013-10-01 — — US disclosed
EP-1833473-B1 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE ARENA PHARM INC (US) 2009-09-09 — — EP disclosed
US-20090197868-A1 5ht2c receptor modulator compositions and methods of use ARENA PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed
US-7514422-B2 5HT2c receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2009-04-07 — — US disclosed
US-20070060568-A1 Obesity therapy; using 3-benzoazepine compound ARENA PHARMACEUTICALS, A DELAWARE CORPORATION 2007-03-15 — — US disclosed
EP-1411881-B9 5HT2C RECEPTOR MODULATORS ARENA PHARM INC (US) 2006-11-15 — — EP disclosed
US-6953787-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2005-10-11 — — US disclosed
EP-1557409-A1 5HT2C receptor modulators Arena Pharmaceuticals, Inc. (US) 2005-07-27 — — EP disclosed
EP-1411881-B1 5HT2C RECEPTOR MODULATORS ARENA PHARM INC (US) 2005-05-04 — — EP disclosed
US-20050020573-A1 Obesity; using 3-benoazepine compound ARENA PHARMACEUTICALS, INC. (US) 2005-01-27 — — US disclosed
US-20030225057-A1 3-Benzoazepine derivatives ARENA PHARMACEUTICALS, INC. (US) 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225057-A1 3-Benzoazepine derivatives HTR2C, HTR1A, HTR3A DRD3 76/4885HTR1A 2/4885HTR2A 13/4885
US-20050020573-A1 Obesity; using 3-benoazepine compound HTR2C, HTR3C, HTR3B DRD3 160/4885HTR1A 9/4885HTR2A 7/4885
US-20070060568-A1 Obesity therapy; using 3-benzoazepine compound HTR2C, HTR3B, HTR3C DRD3 159/4885HTR1A 9/4885HTR2A 8/4885
US-20150087634-A1 5HT2C RECEPTOR MODULATOR COMPOSITIONS HTR2C, HTR2A, HTR5A DRD3 197/4885HTR1A 4/4885HTR2A 2/4885
US-20160024014-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A DRD3 330/4885HTR1A 3/4885HTR2A 2/4885
US-20090197868-A1 5ht2c receptor modulator compositions and methods of use HTR2C, HTR5A, HTR2A DRD3 223/4885HTR1A 6/4885HTR2A 3/4885
US-20150045552-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A DRD3 330/4885HTR1A 3/4885HTR2A 2/4885
US-20160250223-A1 5HT2C RECEPTOR MODULATORS HTR2C, HTR2A, HTR1A DRD3 330/4885HTR1A 3/4885HTR2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.